- Home
- / Annovis Bio
Annovis Bio
Stock Price
$9.8
2024-10-29
Market Capitalization
$127.3 M
2024-10-29
Annovis Bio Summary
Company Summary
- Overview
- Annovis Bio (formerly known as QR Pharma) is a company that develops drugs for chronic neurodegeneration. It focuses on Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). Annovis Bio's lead component is ANVS-401 for the treatment of the aforesaid diseases.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Berwyn, PA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Jeffrey McGroarty, Chief Financial Officer
Jeffrey Cummings, Chief Medical Adviser and SAB Member
Michael Hoffman, Chairman of the Board
Operating MetricsView all
Patents (US)
8
Q3, 2019
Patents (Foreign)
15
Q3, 2019
Patent Applications (US)
2
Q3, 2019
LocationsView all
1 location detected
Berwyn, PA HQ
United States
1055 Westlakes Dr #300Berwyn
Annovis Bio Financials
Summary Financials
- Net income (Q1, 2026)
- ($17.6M)
- Cash (Q1, 2026)
- $14.2M
- EBIT (Q1, 2026)
- ($18.0M)